9390 Stock Chart & Stats
€0.36
€0.00(0.00%)
At close: 4:00 PM EDT
€0.36
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.31 - €0.59
Previous CloseN/A
Volume0.00
Average Volume (3M)1.64K
Market Cap
€36.67M
Enterprise Value€52.82
Total Cash (Recent Filing)€3.50M
Total Debt (Recent Filing)€527.62K
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding96,894,780
10 Day Avg. Volume2,980
30 Day Avg. Volume1,644
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)15.03
Price to Sales (P/S)30.35
P/FCF Ratio-8.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.96Price Target Upside166.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)€2.58M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And High Gross MarginStrong revenue expansion and an approximately 89% gross margin indicate attractive economics on delivered services. If growth converts into operating leverage, the company could build a more scalable virtual-care model, although profitability is not yet established.
Expanded Reimbursed Telehealth AccessThe California network agreement broadens access across commercial, Medicare Advantage, workers’ compensation and auto medical channels. Multiple reimbursed pathways can diversify demand, improve utilization and strengthen Rocket Doctor’s U.S. distribution position over time.
Conservative Leverage And Balance-sheet RepairLow debt relative to equity limits balance-sheet leverage and provides greater flexibility than a heavily debt-funded model. Equity has also recovered from negative levels in 2022–2023, indicating meaningful financial repair despite continued operating losses.
Bears Say
Large Operating And Net LossesOperating expenses remain far above the current revenue base, producing substantial EBIT and net losses despite rapid sales growth. Sustained losses could require continued external funding and make the timing of a viable, self-supporting business model uncertain.
Persistent Cash ConsumptionNegative operating and free cash flow show that the platform does not yet fund its own operations and investment needs. Continued cash burn increases dependence on financing or further revenue scaling, while also limiting resilience if growth requires more spending.
Financing Adds Interest And Dilution RiskThe financing supports U.S. expansion but carries a high cash interest burden and potential equity dilution through conversion and warrants. These terms may increase the cost of scaling and reduce existing shareholders’ ownership if funding needs persist.
9390 FAQ
What was Rocket Doctor AI’s price range in the past 12 months?
Rocket Doctor AI lowest stock price was €0.31 and its highest was €0.59 in the past 12 months.
What is Rocket Doctor AI’s market cap?
Rocket Doctor AI’s market cap is €36.67M.
When is Rocket Doctor AI’s upcoming earnings report date?
Rocket Doctor AI’s upcoming earnings report date is Dec 01, 2026 which is in 94 days.
How were Rocket Doctor AI’s earnings last quarter?
Currently, no data Available
Is Rocket Doctor AI overvalued?
According to Wall Street analysts Rocket Doctor AI’s price is currently Undervalued.
Does Rocket Doctor AI pay dividends?
Rocket Doctor AI does not currently pay dividends.
What is Rocket Doctor AI’s EPS estimate?
Rocket Doctor AI’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rocket Doctor AI have?
Rocket Doctor AI has 96,894,780 shares outstanding.
What happened to Rocket Doctor AI’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rocket Doctor AI?
Currently, no hedge funds are holding shares in DE:9390
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rocket Doctor AI
Rocket Doctor AI Inc., based in Vancouver, Canada, specializes in delivering personalized healthcare information services across the Canadian market. The company develops a mobile application crafted to help users assess their symptoms and effectively manage their health issues, concerns, and ongoing wellness journey. This sophisticated digital health platform also functions as an insightful assessment tool, offering valuable health analytics. Furthermore, Rocket Doctor AI Inc. provides a range of additional solutions, including medical education resources, tools for medical clinics, expert clinical advisory services, and a comprehensive healthcare information hub. Established in 2018, the company was formerly known as Treatment.com AI Inc. and is slated to officially adopt the name Rocket Doctor AI Inc. in August 2025.
9390 Stock 12 Month Forecast
Average Price Target
€0.96
▲(166.49% Upside)
Technical Analysis
Diagnos
―
Vitalhub
―
nDatalyze Corp
―
UniDoc Health Corp
―
DiagnaMed Holdings Corp.
―








